CAJ | 학술논문

目的：探讨伊立替康联合奈达铂治疗复发性小细胞肺癌的疗效和毒副反应。方法31例复发性小细胞肺癌患者均接受伊立替康联合奈达铂治疗，并观察临床治疗效果和毒副反应。结果全组31例中， CR 5例，PR 18例，SD 4例，PD 4例，有效率为74.2%（23/31），疾病控制率为87.1%（27/31），中位生存期为13.2个月，1 a 生存率为64.5%。毒副反应主要为轻度骨髓抑制、消化道反应。结论伊立替康联合奈达铂治疗复发性小细胞肺癌具有一定的有效性和安全性，值得进一步临床研究。
목적：탐토이립체강연합내체박치료복발성소세포폐암적료효화독부반응。방법31례복발성소세포폐암환자균접수이립체강연합내체박치료，병관찰림상치료효과화독부반응。결과전조31례중， CR 5례，PR 18례，SD 4례，PD 4례，유효솔위74.2%（23/31），질병공제솔위87.1%（27/31），중위생존기위13.2개월，1 a 생존솔위64.5%。독부반응주요위경도골수억제、소화도반응。결론이립체강연합내체박치료복발성소세포폐암구유일정적유효성화안전성，치득진일보림상연구。
Objective To investigate the efficacy and toxicities of irinotecan plus nedaplatin in the treatment of recurrent small cell lung cancer. Methods Thirty-one patients with recurrent small cell lung cancer received the irinotecan plus nedaplatin chemotherapy,and the efficacy and toxicities were evaluated. Results Of the 31 cases, CR was observed in the 5 cases,PR in the 18 cases,SD in the 4 cases,PD in the 4 cases,the effective rate was 74. 2%(23 / 31),the disease control rate was 87. 1%(27 / 31),the median survival time was 13. 2 months,1-year survival rate was 64. 5% . The main toxicities were marrow suppression and gastrointestinal reaction. Conclusion Irinotecan plus nedaplatin is effective and safe in the treatment of recurrent small cell lung cancer.